Ketoprofen, lysine and gabapentin cocrystal, pharmaceutical composition and medical use thereof

Through the co-crystals of ketoprofen, lysine and gabapentin, the problems of limited efficacy and major side effects of existing neuropathic pain treatment drugs have been solved, and more efficient and longer-lasting pain relief effects have been achieved.

CN115605455BActive Publication Date: 2024-11-29DOMPE FARMACEUTICI SPA
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
CN202180032215.X
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2021-05-04
Publication Date
2024-11-29
Estimated Expiration
2041-05-04

AI Technical Summary

Technical Problem

Existing neuropathic pain treatments, such as gabapentin, have limited efficacy and many side effects for certain types of pain, especially in lumbosacral pain and inflammatory pain, and their pharmacology and pharmacokinetics The characteristics are not satisfactory.

Method used

A co-crystal of ketoprofen, lysine and gabapentin was developed with a molar ratio of 1:1:2 by suspending, dissolving, cooling and adding ketoprofen, lysine and gabapentin in a suitable solvent. Anti-solvent preparation forms stable eutectics, thereby improving the bioavailability and therapeutic efficacy of the drug.

Benefits of technology

This eutectic significantly improves the pharmacokinetics and efficacy of the drug, especially in the treatment of neuropathic and inflammatory pain, providing faster absorption, higher gastric tolerance and longer duration of action , reducing the occurrence of side effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN115605455B_ABST
    Figure CN115605455B_ABST
Patent Text Reader

Abstract

The present invention relates to a novel co-crystal of ketoprofen, lysine and gabapentin, to a pharmaceutical composition, and to their use in preventing, alleviating or treating pain and / or inflammation.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a co-crystal of ketoprofen, lysine and gabapentin, to a method for preparing the co-crystal, to a pharmaceutical composition comprising the co-crystal, and to use of the co-crystal or the pharmaceutical composition in treating acute or chronic pain, in particular in treating neuropathic or inflammatory pain. Background Art

[0002] Pain is a sensory and emotional experience that is usually caused by actual or potential tissue damage. Pain conditions can be classified as acute or chronic.

[0003] Acute pain is pain that is of short duration (typically less than 3 months) and is usually associated with tissue injury, inflammation, surgery, childbirth, or a transient disease process.

[0004] Chronic pain is considered to be pain that persists beyond normal healing time and therefore lacks the acute warning function of physiological nociception. Typically, pain is classified as chronic when it persists or recurs for more than 3 months.

[0005] Chronic pain can have different causes, including neuropathic pain, chronic inflammatory pain (such as arthritis), or pain of unknown origin (such as fibromyalgia and restless legs syndrome).

[0006] Chronic neuropathic pain is caused by lesions or diseases of the somatic sensory nervous system, which provides information about the body, including the skin, musculoskeletal and internal organs. Many diseases or pathological conditions can lead to damage to sensory neurons, which results in hyperalgesia or allodynia, such as lower back pain, sciatica, postoperative pain, cancer pain, phantom limb pain, HIV pain, diabetic neuropathy pain, herpes zoster pain or trigeminal neuralgia.

[0007] Chronic inflammatory pain is associated with intense inflammation of infectious, autoimmune, or metabolic etiology (eg, rheumatoid arthritis) as well as structural changes affecting bones, joints, tendons, or muscles (eg, osteoarthrosis).

[0008] Treatment for this type of pain often includes the use of NSAIDs, acetaminophen, and other disease-modifying agents.

[0009] Due to its complex etiology, the pharmacological treatment of neuropathic pain is different from the treatment of non-neuropathic pain. Guidelines recommend the use of serotonin and norepinephrine reuptake inhibitors, tricyclic antidepressants, anticonvulsants or topical lidocaine as first-line and second-line drugs for the management of neuropathic pain, and opioids are usually recommended as second-line or third-line therapy (Deng et al., BMC Anesthesiology (2016) 16: 12). Acetaminophen and nonsteroidal anti-inflammatory drugs are essentially ineffective for neuropathic pain.

[0010] Neuroinflammation is a physiological / pathological condition characterized by immune cell infiltration, glial cell activation, and the production of inflammatory mediators in the peripheral and central nervous systems.

[0011] Recent progress shows that the development of neuroinflammation organized in the peripheral nervous system (PNS) and the central nervous system (CNS) is the reason for the sensitization of nociceptive neurons that produce and maintain chronic pain.Neuroinflammation occurs in PNS (i.e., peripheral nerves and ganglia) and CNS (i.e., spinal cord and brain), characterized in that the generation of leukocyte infiltration and inflammatory mediators at these positions increases.The transportation of different types of leukocytes in PNS and CNS occurs with different time distributions.Neuroinflammation is manifested as the activation of glial cells (such as Schwann cells in nerves, satellite glial cells and microglia in ganglia and astrocytes and oligodendrocytes in spinal cord and brain).The activation of glial cells causes the generation of glial mediators that can regulate pain sensitivity.

[0012] Neuroinflammation is a localized form of inflammation, which means it is more effective than systemic inflammation in initiating and maintaining pain, but it can be difficult to detect clinically. For example, fibromyalgia, a chronic muscle pain condition, was previously considered an atypical pain condition because no overt pathology and inflammation could be detected in affected patients. However, recent studies have identified small nerve fiber neuropathy in fibromyalgia patients, which may be both a consequence and a cause of chronic neuroinflammation. Neuroinflammation appears to be permanent in patients with chronic pain, but also occurs in non-chronic conditions such as post-surgical pain.

[0013] Currently available therapies lack efficacy in managing neuroinflammatory disorders, thus creating a need to discover new specific and safe drugs for the treatment of unmet medical needs associated with acute or chronic neuroinflammatory processes (Ru-Rong Jil. Nat. Rev. Drug Discov. 2014 Jul;13(7):533-548).

[0014] Gabapentin is an anticonvulsant synthetic analog of the neurotransmitter gamma-aminobutyric acid (GABA) of formula (I)

[0015]

[0016] Although its exact mechanism of action is unknown, gabapentin appears to inhibit excitatory neuronal activity. The molecule was originally developed as a chemical analog of gamma-aminobutyric acid to reduce spinal reflexes to treat spasticity, but it was found to have no activity on the GABAergic system. Its mechanism of action involves binding to calcium channels expressed in several areas of the central nervous system and spinal cord where these are expressed. Calcium channels are located in presynaptic terminals where they control the release of neurotransmitters.

[0017] Gabapentin was approved in 1993 as an adjunctive treatment for partial seizures in adults and children. More recently, gabapentin has also been approved for the treatment of chronic pain, particularly neuropathic pain syndromes. It is also claimed to be beneficial for several other clinical conditions, such as anxiety, bipolar disorder, and hot flashes. Gabapentin has also been shown to be effective in the treatment of fibromyalgia at high doses (Moore et al., Cochrane Database Syst Rev. 2014 Apr 27; (4): CD007938; Deng et al., BMC Anesthesiology (2016) 16: 12).

[0018] However, many studies have shown that when gabapentin is used alone for pain treatment, the pharmacological and pharmacokinetic characteristics are unsatisfactory, such as lack of efficacy in specific types of pain, side effects or delayed response. In fact, gabapentin is slowly absorbed after oral administration, reaching the highest level in plasma within 3-4 hours (Quintero, Journal of Experimental Pharmacology 2017: 9 13-21).

[0019] Gabapentin plasma levels do not increase proportionally if the dose is increased, so careful titration on an individual basis is required at the beginning of treatment; gabapentin does not bind to plasma proteins.

[0020] Gabapentin is neither inhibited nor metabolized by liver enzymes; in addition, gabapentin can be excreted by the renal system with an excretion half-life of approximately 6 hours. The most common side effects of gabapentin are drowsiness (20%), dizziness (18%), ataxia (13%), and fatigue (11%).

[0021] Because of the short half-life of gabapentin, oral doses of gabapentin are administered three times daily (tds). Rapid titration can be achieved as follows: a dose of 300 mg once daily on the first day (usually at bedtime to minimize sedation), then 300 mg twice daily on the second day, and 300 mg tds on the third day. If efficacy is not achieved at this dose, the dose can be further increased.

[0022] The recommended starting dose for the treatment of neuropathic pain is 300 mg three times daily, titrated to a maximum of 3600 mg / day if necessary, but doses as high as 4200 mg have been reported when limited or no efficacy is observed (MARose, Anaesthesia, 2002, 57, pp. 451-462).

[0023] For example, gabapentin is not recommended for the treatment of lumbosacral pain because it shows little efficacy and an increased risk of side effects (Low back pain and sciatica in over 16s: assessment and management, National Institute for Health and Care Excellence NICE Guidelines 2016).

[0024] Furthermore, gabapentin has little activity against inflammatory pain.

[0025] It has also been shown that the therapeutic effect of gabapentin in the treatment of osteoarthritis only begins after extended administration for 3 months (Enteshari-Moghaddam et al., Clinical Rheumatology 2019:38, 2873-2880).

[0026] Applicants have conducted studies to improve the properties of gabapentin with the goal of improving the activity of the molecule against painful conditions, extending efficacy to other pain syndromes, and potentially reducing dose-related side effects.

[0027] In particular, Applicants have investigated the combination of gabapentin with ketoprofen, in particular with ketoprofen lysine.

[0028] Ketoprofen of formula II: (RS)-2-(3-benzoylphenyl)-propionic acid is a well-established nonsteroidal anti-inflammatory drug (NSAID) with analgesic and antipyretic effects

[0029]

[0030] Due to its high tolerability, ketoprofen is one of the most widely used NSAIDs in clinical practice, both for the treatment of severe inflammatory conditions and for analgesia and antipyretics by inhibiting the body's production of prostaglandins.

[0031] The currently used pharmaceutical composition containing ketoprofen has a racemate as an active ingredient in which two enantiomers S(+) and R(-) are present in an equimolecular ratio.

[0032] Ketoprofen pharmaceutical compositions currently used for oral use may contain the active ingredient in the form of the free acid, however, the solubility of the active ingredient in water is very low and thus the bioavailability is low.

[0033] In order to improve the dissolution profile and bioavailability of the active ingredient, salts of ketoprofen are also advantageously used.

[0034] These salts are used, for example, by oral administration for the treatment of those pathologies of the rheumatoid and chronic type which require the administration of the drug in high doses, continuously and for a long period of time, and for painful manifestations which require an immediate analgesic effect.

[0035] In particular, the salt of ketoprofen with the amino acid lysine, while presenting parallel pharmacological characteristics and similar anti-inflammatory-analgesic efficacy compared to the free acid, offers the advantage of a considerably higher solubility in water, allowing rapid and almost complete absorption of the compound, ensuring rapid onset of action and greater gastric tolerance.

[0036] Ketoprofen is commonly used for the treatment of inflammatory pain associated with arthritis, severe dental pain, musculoskeletal pain, neuropathic pain (such as sciatica), postherpetic neuralgia, and referred pain from radiculopathy.

[0037] The mechanism of action of ketoprofen is primarily based on the inhibition of the biosynthesis of prostaglandins, prostacyclins, and thromboxanes.

[0038] As described in European patent applications Nos. EP18215336.1 and EP19219293.8 and international patent application PCT / EP2019 / 025464, ketoprofen and lysine may combine to form salts or co-crystals (polymorphs) with different crystalline forms, depending on the process conditions. Summary of the invention

[0039] Applicants unexpectedly discovered during the course of these studies that ketoprofen and lysine form new stable co-crystals with gabapentin in a molar ratio of 1:1:2.

[0040] Therefore, one object of the present invention is a co-crystal of ketoprofen, lysine and gabapentin, wherein the molar ratio of the components is 1:1:2.

[0041] The co-crystal is characterized by the following XRPD diffraction peaks: 3.6, 6.3, 18.6 and 21.7 degrees 2θ ± 0.2 degrees 2θ, and is preferably further characterized by the following XRPD diffraction peaks: 9.6, 17.2 and 20.5 degrees 2θ ± 0.2 degrees 2θ.

[0042] A further object of the present invention is a method for preparing the co-crystal of the present invention, comprising:

[0043] a) suspending ketoprofen, lysine and gabapentin in a suitable solvent at a molar ratio of 1 / 1 to 1.5 / 2 to 2.5,

[0044] b) dissolving ketoprofen, lysine and gabapentin, optionally by heating the suspension and / or under stirring, until a clear solution is obtained,

[0045] c) then cooling the solution, and

[0046] d) optionally adding an anti-solvent.

[0047] A further object of the present invention is a pharmaceutical composition comprising the co-crystal of the present invention and at least one pharmaceutically acceptable excipient.

[0048] A further object of the present invention is a pharmaceutical composition comprising the co-crystal according to the invention and at least one further pharmaceutically active ingredient.

[0049] A further object of the present invention is the co-crystal of the present invention for use as a medicament.

[0050] A further object of the present invention is the co-crystal of the present invention for use in the treatment of pain and / or inflammation.

[0051] A further object of the present invention is a method for treating pain and / or inflammation comprising administering to a patient an effective amount of a co-crystal of the present invention.

[0052] definition

[0053] For the purpose of the present invention, the term "pharmaceutically acceptable excipient" refers to a substance that does not have any pharmacological effect itself and does not produce adverse reactions when administered to mammals, preferably humans.

[0054] For the purposes of the present invention, the term "room temperature" refers to a temperature range of 18 to 25°C.

[0055] For purposes of the present invention, the term "co-crystal" refers to a multi-component system in which all components are solid under ambient conditions in their pure form. The components coexist at the molecular level within a single crystal. At least some of the components are linked by non-covalent, non-ionic interactions.

[0056] For the purposes of the present invention, the term "pain" refers to pain caused by disorders of different nature and origin, such as: headache or headache: primary (and therefore not related to other factors or diseases) and secondary (and therefore dependent on trauma, injury and different diseases); toothache: a condition in which abscesses or caries cause pain in the dental pulp (where blood vessels and nerves are numerous); menstrual pain: pain and headache in the abdomen and lower abdomen caused by the typical hormonal changes during menstruation; neuralgia or severe nerve pain due to strain, trauma and infection; muscle pain or myalgia: pain at the level of the muscle when using or touching the muscle, due to sudden contraction or trauma; bone and joint pain, such as inflammation of the joints (of bones, cartilage, ligaments and tendons) after trauma, old age, strain and injury.

[0057] For the purposes of the present invention, the term "inflammation" refers to the organism's localized response to cellular injury, characterized by capillary dilation, leukocyte infiltration, redness, heat, and pain, which serves as a mechanism to initiate the elimination of noxious substances and damaged tissue.

[0058] For the purposes of the present invention, the term "anti-solvent" refers to a solvent in which a compound is insoluble or nearly insoluble.

[0059] The terms "about" and "approximately" herein refer to the range of experimental errors that may occur in the measurements. BRIEF DESCRIPTION OF THE DRAWINGS

[0060] Figure 1 :Powder X-ray diffraction pattern of ketoprofen-lysine-gabapentin 1:1:2 cocrystal

[0061] Figure 2 : Powder X-ray diffraction patterns of ketoprofen-lysine-gabapentin 1:1:2 cocrystal and ketoprofen-lysine-gabapentin 1:1:1 cocrystal

[0062] Figure 3 :DSC thermogram of ketoprofen-lysine-gabapentin 1:1:2 cocrystal

[0063] Figure 4 :DSC thermogram of ketoprofen-lysine-gabapentin 1:1:1 cocrystal

[0064] Figure 5 :DSC thermogram of ketoprofen lysine co-crystal Form I

[0065] Figure 6 :DSC thermogram of gabapentin

[0066] Figure 7 : Ketoprofen-Lysine-Gabapentin 1:1:2 Cocrystal 1 H-NMR spectrum (400 MHz, D2O).

[0067] Figure 8 : Ketoprofen-Lysine-Gabapentin 1:1:2 Cocrystal 13 C-CPMAS ss-NMR.

[0068] Explanation of symbols in the drawings: KL-GAB Co-xx ketoprofen lysine gabapentin cocrystal. DETAILED DESCRIPTION

[0069] An object of the present invention is a co-crystal of ketoprofen, lysine and gabapentin, wherein the molar ratio of the components is 1:1:2.

[0070] The solid state 13 C-NMR analysis is consistent with that in the cocrystal of the present invention, the carboxyl group of ketoprofen is deprotonated and binds to the protonated lysine ε-NH3 through an ionic bond. + The groups interact to form a neutral salt. Ketoprofen lysine neutral salt interacts with two molecules of gabapentin via non-ionic bonds.

[0071] The co-crystals of the present invention are further characterized by the following XRPD diffraction peaks: 3.6, 6.3, 18.6 and 21.7 degrees 2θ ± 0.2 degrees 2θ, the error range of the value indicated by each peak is ± 0.2 degrees 2θ, preferably further characterized by the following XRPD diffraction peaks: 9.6, 17.2 and 20.5 degrees 2θ ± 0.2 degrees 2θ, such as Figure 1 And as shown in Table 2.

[0072] This crystalline form of the co-crystal of the present invention is referred to herein as Form I.

[0073] Other polymorphs of the co-crystals of the present invention are also within the scope of the present invention.

[0074] The co-crystals of the present invention are further characterized by: Figure 3 The DSC thermogram of the eutectic shows a sharp endothermic peak corresponding to a melting point of 143.5 °C and an onset of 139.6 °C. Figure 7 Liquid 1 H-NMR spectra and the related assignments in Table 4, and Figure 8 Solid 13 C CPMAS and related assignments in Table 5.

[0075] In the co-crystal of the present invention, ketoprofen may be racemic (S,R)-ketoprofen, (S)-ketoprofen or (R)-ketoprofen or any mixture thereof.

[0076] In one embodiment, the ketoprofen is (S)-ketoprofen (also known as DexKetoprofen).

[0077] In another embodiment, the ketoprofen is (R)-ketoprofen.

[0078] In the co-crystals of the present invention, lysine may be racemic (S,R)-lysine, (S)-lysine or (R)-lysine or any mixture thereof, preferably the natural amino acid (S)-lysine (also known as L-lysine).

[0079] In one embodiment, the co-crystal of the invention comprises (S)-ketoprofen.

[0080] In one embodiment, the co-crystals of the invention comprise (S)-lysine.

[0081] In one embodiment, the co-crystal of the invention comprises (S)-ketoprofen and (S)-lysine.

[0082] The co-crystals of the present invention may exist in unsolvated forms as well as solvated forms including hydrated forms.

[0083] The co-crystals of the present invention are easily obtainable and stable.

[0084] The co-crystals of the present invention may exhibit improved pharmaceutical properties, pharmacokinetics and efficacy in painful conditions, especially when compared to gabapentin or ketoprofen alone, and even when compared to mixtures thereof.

[0085] A further object of the present invention is a method for preparing the co-crystal of the present invention, said method comprising:

[0086] a) suspending ketoprofen, lysine and gabapentin in a suitable solvent at a molar ratio of 1 / 1 to 1.5 / 2 to 2.5,

[0087] b) dissolving ketoprofen, lysine and gabapentin, optionally by heating the suspension and / or under stirring, until a clear solution is obtained,

[0088] c) then cooling the solution, and

[0089] d) optionally adding an anti-solvent.

[0090] In the present method, the raw material of Ketoprofen can be Ketoprofen free acid or Ketoprofen salt, preferably Ketoprofen lysine salt, or any Ketoprofen lysine eutectic. In the case of Ketoprofen free acid or the Ketoprofen salt that is different from lysine salt, add lysine, preferably the lysine of neutral form. Lysine is preferably used with the molar amount identical with Ketoprofen.

[0091] Ketoprofen and lysine may be in any optical form, ie any pure optical isomer or any mixture of optical isomers, including racemates.

[0092] In step a) of the present process, the molar ratio of gabapentin to ketoprofen is preferably from 2:1 to 2.5:1, more preferably from 2:1 to 2.2:1, even more preferably about 2:1.

[0093] In one embodiment, the molar ratio of ketoprofen:lysine:gabapentin in step a) is about 1:1:2.

[0094] In the present process, suitable solvents are alcohols (preferably methanol and ethanol), esters (preferably ethyl acetate), ethers (preferably tetrahydrofuran and tert-butyl methyl ether) or aromatic solvents (preferably toluene).

[0095] Preferably, step b) is carried out by heating at the reflux temperature of the solvent.

[0096] Preferably, the solution from step b) is cooled at room temperature.

[0097] Preferably, the solution from step b) is cooled at room temperature and filtered.

[0098] Preferably, precipitation of the co-crystals is facilitated by the addition of an anti-solvent.

[0099] The present method provides the co-crystals of the present invention in high yield. It is simple and can be easily scaled up on an industrial level.

[0100] According to one embodiment, in step a) of the process according to the invention, ketoprofen and lysine may be present as preformed salts or co-crystals in any polymorphic form.

[0101] The starting materials gabapentin, ketoprofen and ketoprofen lysine salt or co-crystals used to make the co-crystals of the present invention may be prepared according to synthetic methods previously disclosed and well known to organic chemists of ordinary skill.

[0102] For example, ketoprofen lysine salt can be prepared as described in GB1497044A and BE882889.

[0103] For example, ketoprofen lysine cocrystal Form I can be prepared as described in European Patent Application No. EP18215336.1 or International Patent Application PCT / EP2019 / 025464.

[0104] For example, ketoprofen lysine cocrystal Form IV can be prepared as described in EP19219293.8.

[0105] According to an alternative embodiment, the ketoprofen is in the free acid form and / or the lysine is in the neutral form.

[0106] In the present preparation method, gabapentin is preferably used in its neutral form (zwitter ion inner salt) or in any acid or base salt form, for example, as gabapentin hydrochloride or gabapentin sodium salt.

[0107] Preferably, gabapentin is used in its neutral form.

[0108] Gabapentin may be in any polymorphic form.

[0109] Furthermore, the present invention relates to a pharmaceutical composition comprising the ketoprofen-lysine-gabapentin co-crystal according to the present invention, in particular the ketoprofen-lysine-gabapentin co-crystal as defined above, and at least one pharmaceutically acceptable excipient.

[0110] For example, a composition according to the invention may contain 0.5-60 wt% of a co-crystal as defined herein and 40-99.5 wt% of one or more pharmaceutically acceptable excipients.

[0111] The choice of excipient will to a large extent depend on factors such as the particular mode of administration, its effect on solubility and stability, and the nature of the dosage form.

[0112] The pharmaceutical composition according to the present invention may be in any form suitable for application to humans and / or animals (preferably humans, including infants, children and adults), and may be produced by standard procedures known to those skilled in the art.

[0113] The pharmaceutical composition of the present invention is preferably an oral solid composition, such as capsules, pills, tablets, cachets, chewable dosage forms, powders, lozenges, granules, orally soluble granules, suspensions, emulsions, sprays, or dry powders to be reconstituted with a liquid medium.

[0114] The pharmaceutical composition may additionally contain one or more pharmaceutically acceptable excipients, such as fillers, binders, glidants, disintegrants, flow regulators and release agents.

[0115] Suitable excipients are disclosed, for example, in “Handbook of Pharmaceutical Excipients”, 3rd edition, published by AH Kibbe, American Pharmaceutical Association, Washington, USA and Pharmaceutical Press, London.

[0116] Suitable fillers include, for example, lactose (monohydrate, spray dried monohydrate, anhydrous, etc.), mannitol, xylitol, dextrose, sucrose, sorbitol, microcrystalline cellulose, starch, dibasic calcium phosphate dihydrate, and dibasic calcium phosphate.

[0117] The amount of filler may be 0-80% by weight, preferably 10-60% by weight, relative to the total weight of the composition.

[0118] Suitable binders are, for example, polyvinyl pyrrolidone, microcrystalline cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, methyl cellulose, hydroxyethyl cellulose, sugars, dextran, corn starch, gelatin, polyethylene glycol, natural and synthetic gums, pregelatinized starch.

[0119] The amount of the binder may be 0-80% by weight, preferably 10-60% by weight, relative to the total weight of the composition.

[0120] Binders are generally used to impart cohesiveness to tablet formulations.

[0121] Suitable glidants are, for example, alkaline earth metal salts of fatty acids (eg, stearic acid), such as magnesium stearate, calcium stearate, zinc stearate, sodium stearyl fumarate, and a mixture of magnesium stearate and sodium lauryl sulfate.

[0122] The amount of the glidant may be 0-2% by weight, preferably 0.5-1.5% by weight, relative to the total weight of the composition.

[0123] Suitable disintegrants are, for example, cross-linked sodium carboxymethylcellulose, sodium carboxymethyl starch, cross-linked polyvinyl pyrrolidone (crospovidone), sodium carboxymethyl glycolate, sodium starch glycolate, sodium carboxymethylcellulose, calcium carboxymethylcellulose, polyvinyl pyrrolidone, methylcellulose, microcrystalline cellulose, lower alkyl-substituted hydroxypropyl cellulose, starch, pregelatinized starch, sodium alginate and sodium bicarbonate.

[0124] The amount of the disintegrant may be 0-20% by weight, preferably 1-15% by weight, relative to the total weight of the composition.

[0125] Suitable flow regulators are, for example, colloidal silicon dioxide. The amount of flow regulator may be 0-8 wt%, preferably 0.1-3 wt%, relative to the total weight of the composition.

[0126] Suitable mold release agents include, for example, talc. The amount of the mold release agent may be 0-5% by weight, preferably 0.5-3% by weight, relative to the total weight of the composition.

[0127] The solid composition may be coated, preferably film-coated.

[0128] Suitable coating agents are, for example, cellulose derivatives, poly(meth)acrylates, polyvinyl pyrrolidone, polyvinyl acetate phthalate, and / or shellac or natural rubber such as carrageenan.

[0129] In many cases it will be advantageous or even necessary to deliver the co-crystals of the invention in solid form, for example by installation of a solid implant composition into an appropriate body tissue or cavity.

[0130] The implant may comprise a matrix of a biocompatible and bioerodible material in which particles of the co-crystals of the invention are dispersed, or spheres or isolated crystal cells in which a liquid mixture of the co-crystals of the invention may be embedded. Ideally, the matrix will be broken down and completely absorbed by the body. It is also preferred that the composition of the matrix be selected to provide controlled, sustained and / or delayed release of the co-crystals of the invention over an extended period of time.

[0131] Alternatively, the co-crystals of the invention may be formulated as a solid, semi-solid or thixotropic liquid for administration as an implanted depot providing modified release of the active compound.

[0132] The compositions of the invention may be administered topically to the skin or mucosa, ie, dermal, epidermal, subdermal or transdermal.

[0133] The compositions of the present invention may be administered sublingually or via a suppository.

[0134] Typical formulations for this purpose include pour-on, spot-on, dip, spray, mousse, shampoo, powder formulations, gel, hydrogel, lotion, cream, ointment, dusting powder, dressing, foam, film, skin patch, wafer, implant, reservoir, sponge, fiber, bandage, microemulsion or soluble particles. Liposomes may also be used.

[0135] The pharmaceutical composition of the present invention may be a solid composition for the extemporaneous preparation of a solution for oral or parenteral administration (eg to be administered by intramuscular, intraperitoneal or intravenous injection).

[0136] The pharmaceutical composition of the present invention can be prepared by methods well known to those skilled in the art.

[0137] The compositions of the present invention may be of the immediate release, delayed release, modified release, sustained release, pulsed release or controlled release type.

[0138] According to a further embodiment, the pharmaceutical composition of the present invention may comprise the co-crystal of the present invention and at least one other pharmaceutically active ingredient.

[0139] The additional pharmaceutically active ingredient will be determined by the circumstances under which the therapeutic agent of the invention is administered.

[0140] A further object of the present invention is the co-crystal of the present invention for use as a medicament.

[0141] The medical use may be therapeutic, preventive or palliative.

[0142] The combination of two active ingredients in the same crystal may present several advantages for the medical use of the present invention.

[0143] First, gabapentin and ketoprofen lysine are linked in the cocrystal and generally behave as a single chemical entity, thereby facilitating therapeutics, formulations, dosing, and the like.

[0144] Furthermore, the two active ingredients complement each other in treatment, particularly in the treatment of pain, and possibly in the treatment of various other diseases or symptoms.

[0145] Another advantage is that combining the two active ingredients into one unique species can achieve better pharmacokinetics / pharmacodynamics (PKPD), including better penetration of the blood-brain barrier, which can help treat pain.

[0146] The co-crystals and compositions of the present invention may show synergistic activities of the active ingredients gabapentin and ketoprofen lysine.

[0147] This synergistic effect may provide enhanced clinical efficacy, or reduce the required dosage of each compound, resulting in reduced side effects, while maintaining or enhancing the clinical effectiveness of the compounds and treatment, compared to when the individual components of the co-crystal are administered alone.

[0148] For example, patients may experience improved pain and / or reduced frequency and severity of inflammation. In addition, patients may benefit from the longer duration of action of cocrystal treatment compared to treatment with gabapentin or with ketoprofen lysine or with a combination thereof.

[0149] It is necessary for a skilled technician (such as a physician or veterinarian) not only to determine the preferred route of administration and the corresponding dosage form and amount, but also said technician must determine the dosage regimen.

[0150] The daily dose for humans and animals may vary according to basic factors of the respective species or other factors (eg age, sex, body weight or degree of disease, etc.).

[0151] The daily dose of the co-crystal according to the invention for humans preferably provides an amount of 25 to 200 mg, preferably 25 to 100 mg, more preferably about 50 mg of ketoprofen acid form, 1 to 8 times a day, preferably 1 to 4 times a day, resulting in a very low total amount of gabapentin compared to a normal dose of gabapentin alone.

[0152] A further object of the present invention is the co-crystal of the present invention for use in the treatment of pain and / or inflammation.

[0153] The co-crystals and compositions of the present invention are preferably used for the treatment of pain, preferably acute or chronic pain and inflammation, preferably neuroinflammation.

[0154] Preferably, the pain is selected from headache, toothache, menstrual pain, muscle pain, neuropathic pain, diabetes, neuropathy, pain associated with neuroinflammation, cancer pain, osteoarthritis, low back pain, sciatica, fibromyalgia, trigeminal neuralgia, post-surgical and post-operative pain, post-herpetic neuralgia, rheumatoid arthritis, ankylosing spondylitis, frozen shoulder, phantom limb pain or HIV pain.

[0155] A further object of the present invention is a method for treating pain and / or inflammation comprising administering to a patient an effective amount of a co-crystal of the present invention.

[0156] Experimental Section

[0157] The preparation of co-crystals of ketoprofen, lysine and gabapentin, their analytical and biological characterization are described below.

[0158] 1. Synthesis of Ketoprofen-Lysine-Gabapentin 1:1:2 Cocrystal

[0159] Ketoprofen lysine cocrystal Form I (3.0 g, 1.0 eq.) was prepared as described in European patent application No. EP18215336.1 or international patent application PCT / EP2019 / 025464 and dissolved in 60 ml of boiling methanol with gabapentin (2.56 g, 2.0 eq.). The clear solution was cooled at room temperature, finely filtered (0.45 μm HPLC filter) and then added to 240 ml of THF under stirring. Solid precipitation occurred at about 45 minutes and the suspension was stirred at 25 ° C for 2 hours (300 rpm). The solid product was isolated by vacuum filtration on filter paper, washed with methanol (2×3 ml) and then squeezed under a nitrogen stream for about 10 minutes. The solid was gently ground and then dried overnight at 40 ° C and 30 mbar to obtain 4.8 grams of the desired product as a white solid (yield: 86%).

[0160] 2. XRPD analysis

[0161] XRPD analysis was performed using the following instrumentation and under the conditions reported in Table 1 below:

[0162] Table 1

[0163]

[0164]

[0165]

[0166] Figure 1The powder X-ray diffraction pattern of ketoprofen-lysine-gabapentin 1:1:2 cocrystals is reported. Figure 2 A comparison between the powder X-ray diffraction patterns of ketoprofen-lysine-gabapentin 1:1:1 cocrystal and 1:1:2 cocrystal is reported.

[0167] Table 2 below reports the XRPD peak list for the ketoprofen-lysine-gabapentin 1:1:2 cocrystal:

[0168] Table 2. XRPD peak list of ketoprofen-lysine-gabapentin 1:1:2 cocrystal

[0169]

[0170] 3. Thermal analysis

[0171] DSC analysis

[0172] The analysis was carried out using the instrument DSC Mettler Toledo DSC1.

[0173] The sample was weighed in an aluminum pan sealed with an aluminum lid. The analysis was performed by heating the sample from 25°C to 320°C at a rate of 10 K / min under the conditions shown in Table 3 below:

[0174] Table 3

[0175]

[0176] A sample of ketoprofen-lysine-gabapentin 1:1:2 cocrystal was analyzed. The DSC thermogram is shown in Figure 3 middle.

[0177] Figure 4 , Figure 5 and Figure 6 The thermograms of ketoprofen-lysine-gabapentin 1:1:1 cocrystal, ketoprofen-lysine cocrystal Form I, and gabapentin were reported, respectively.

[0178] Figure 3 The DSC thermogram of shows a single endothermic event at 143.55 °C (onset 139.57 °C), which is associated with sample melting and degradation. Figures 4 to 6 The endothermic peaks in the thermograms of the ketoprofen-lysine-gabapentin 1:1:1 cocrystal, ketoprofen lysine cocrystal Form I, and gabapentin are shown to be distinctly different.

[0179] 4. Liquid and solid state NMR

[0180] The results were recorded on a Bruker Avance3 400 MHz instrument with tetramethylsilane (TMS) as the internal standard in the specified solvents.1 H-NMR spectra. Chemical shifts are reported in parts per million (ppm) relative to an internal standard. Abbreviations are used as follows: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, dd = doublet of doublets, br = broad. Coupling constants (J values) are given in Hertz (Hz).

[0181] Solid-state preparation of ketoprofen-lysine-gabapentin cocrystals and pure gabapentin using a Jeol ECZR 600 instrument 13 CCPMAS spectrum, for 1 H and 13 C nuclei, operating at 600.17 MHz and 150.91 MHz, respectively. The powder samples were loaded into a cylindrical zirconia rotor with an outer diameter of 3.2 mm and a volume of 60 μl. Samples were collected from each batch and used to fill the rotor without further preparation. 13 C CPMAS spectrum, rotation rate 20kHz, using ramp cross-polarization pulse sequence, 90° 1 The H pulse was 2.1 μs and the contact time was 3.5 ms. An optimized recycle delay of 5.7 s (ketoprofen-lysine-gabapentin) or 100 s (GAB) was used for the number of scans of 2200 (ketoprofen-lysine-gabapentin) or 20 (GAB). For each spectrum, a two-pulse phase modulation (TPPM) decoupling scheme was used with an RF field of 108.5 kHz. Calibration was performed using the methylene signal of an external glycine standard (43.7 ppm). 13 C chemical shift scale. 13 C T1- 1 H analysis, 12 spectra were obtained with 350 scans at different relaxation delays calculated by exponential algorithm in the range of 0.1 to 60 s using Delta v5.2.1 software. Spectra were acquired at room temperature with a rotation speed of 20 kHz using a ramped cross-polarization pulse sequence at 90° 1 The H pulse was 2.1 μs and the contact time was 2 ms.

[0182] Ketoprofen-Lysine-Gabapentin 1:1:2 Cocrystal 1 H-NMR spectrum

[0183] Ketoprofen-Lysine-Gabapentin Cocrystal 1 H-NMR spectrum confirmed that ketoprofen-lysine-gabapentin existed in the sample in a stoichiometric ratio of 1:1:2.

[0184] The multiplicity and assignment of signals consistent with the atom numbering shown in Scheme 1 are reported in Table 4 below:

[0185] Solution 1

[0186] Ketoprofen

[0187] Lysine Gabapentin

[0188] Table 4: 1 H-NMR ((KET:LYS:GAB ratio 1:1:2)

[0189] δppm Multiplicity distribute 7.75-7.78 m,2H Ar KET 7.69-7.72 m,2H Ar KET 7.60-7.62 m,2H Ar KET 7.48-7.56 m,3H Ar KET 3.71 t,J=6.4Hz,1H CH(2')LYS 3.69 quart.,J=7.2Hz,1H CH(2)KET 2.96 t,J=7.6Hz,2H <![CDATA[CH2(6')LYS]]> 2.95 s,4H <![CDATA[CH2(9”)GAB]]> 2.36 s,4H <![CDATA[CH2(2”)GAB]]> 1.79-1.85 m,2H <![CDATA[CH2(5')LYS]]> 1.62 quint.,J=7.6Hz,2H <![CDATA[CH2(3')LYS]]> 1.41 d,J=7.2Hz,3H CH3(3)KET 1.29-1.52 m,22H <![CDATA[CH2(4”,5”,6”,7”,8”)GAB;CH2(4')LYS]]>

[0190] Ketoprofen-Lysine-Gabapentin 1:1:2 Cocrystal 1 H-NMR spectrum (400 MHz, D2O) is shown in Figure 7 middle.

[0191] Solid-state preparation of ketoprofen-lysine-gabapentin 1:1:2 cocrystal 13 C CPMAS spectrum

[0192] pass 13 The C-CPMAS spectrum confirmed the new homogeneous phase of ketoprofen-lysine-gabapentin. The stoichiometry was estimated to be 1:1:2, with one independent ketoprofen, lysine molecule and two gabapentin molecules in the unit cell. The ketoprofen carboxyl group was deprotonated and bound to the protonated lysine ε-NH3 through ionic bonds. + The groups interact to form a neutral salt. Ketoprofen lysine neutral salt interacts with two molecules of gabapentin through non-ionic bonds to form a cocrystal. Lysine and gabapentin are both in a zwitterionic state in the new crystal form.

[0193] The characteristic solid state 13 C NMR resonance:

[0194] Table 5: Solid State 13 C-NMR

[0195] <![CDATA[ 13 Cδ(ppm)]]> distribute 194.5 10 181.4 1 178.9 1' 178.7 1” 178.1 1” 145.9 Aromatic Cq 139.6 Aromatic Cq 136.2 Aromatic Cq 135.5 Aromatic CH 132.9 Aromatic CH 131.2 Aromatic CH 130.2 3 aromatic CH 127.8 2 aromatic CH 125.2 Aromatic CH 54.1 2' 49.8 9” 48.3 2 42.5 6' 37.1 2”+4” or 8” 36.8 3'+4" or 8" 34.6 6” 30.1 5'+3” 26.1 4' 25.2 3 23.1 5” or 7” 21.1 5” or 7”

[0196] Figure 8 Ketoprofen-Lysine-Gabapentin 1:1:2 cocrystal is shown 13 C CPMAS NMR spectrum.

[0197] All signals in the spectrum of the ketoprofen-lysine-gabapentin cocrystal are similarly 1 The H T1 value (about 6.5 s) is characterized, which means that spin diffusion is active between the molecules of ketoprofen, lysine and gabapentin, that is, the four molecules are in the same unit cell.

[0198] Four different carboxylic / carboxylate group resonances were observed at 181-178 ppm, suggesting a 1:1:2 stoichiometric ratio for the ketoprofen-lysine-gabapentin system.

[0199] Two molecules of gabapentin are zwitterions: their carboxylate groups are in deprotonated form in 1:1:2 ketoprofen-lysine-gabapentin at 178.7 ppm and 178.1 ppm.

[0200] The zwitterionic carboxylate of lysine in 1:1:2 ketoprofen-lysine-gabapentin is at 178.9 ppm, which is due to the strong hydrogen bonding involved in the carboxylate group. Lysine should be in the zwitterionic form.

[0201] Finally, the carboxyl group of ketoprofen in 1:1:2 ketoprofen-lysine-gabapentin was at 181.4 ppm.

Claims

1. A co-crystal of ketoprofen, lysine and gabapentin, wherein the molar ratio of the components is 1:1:2; The cocrystals are characterized by the following XRPD diffraction peaks: 3.6±0.2, 6.3±0.2, 18.6±0.2, and 21.7±0.2 degrees 2θ; and The co-crystals were further characterized by the following XRPD diffraction peaks: 9.6 ± 0.2, 17.2 ± 0.2, and 20.5 ± 0.2 degrees 2Θ.

2. The co-crystal of claim 1, further characterized by one or more of the following: As reported in the DSC thermogram in Figure 3, the endothermic peak corresponds to a melting point of about 143.5 °C. As reported in Figure 7 and Table 4, the liquid 1 H-NMR signals, and As shown in Figure 8 and Table 5, the solid 13 C CPMAS signal.

3. The co-crystal of claim 1, wherein the ketoprofen is (S)-ketoprofen and / or the lysine is (S)-lysine.

4. Use of the co-crystal according to any one of claims 1 to 3 in the preparation of a medicament for preventing, alleviating or treating pain and / or inflammation.

5. The use according to claim 4, wherein the pain is acute or chronic pain.

6. The use according to claim 4, wherein the pain is selected from the group consisting of: dental pain, menstrual pain, muscle pain, neuropathic pain, cancer pain, fibromyalgia, phantom limb pain or HIV pain.

7. The use according to claim 4, wherein the pain is selected from the group consisting of pain associated with neuroinflammation, post-surgical and post-operative pain, post-herpetic neuralgia, low back pain, sciatica and trigeminal neuralgia.

8. The use according to claim 4, wherein the pain is selected from headache.

9. The method according to claim 4, wherein the pain is selected from the group consisting of pain caused by diabetic neuropathy, osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and frozen shoulder.

10. A pharmaceutical composition comprising the co-crystal according to any one of claims 1 to 3 and at least one pharmaceutically acceptable excipient.

11. The pharmaceutical composition according to claim 10, comprising 0.5-60 wt% of the co-crystal and 40-99.5 wt% of one or more pharmaceutically acceptable excipients.

12. The pharmaceutical composition according to claim 10 or 11, which is an oral solid composition.

13. A method for preparing a co-crystal according to any one of claims 1 to 3, wherein include: a) suspending ketoprofen, lysine and gabapentin in a solvent of methanol or ethanol at a molar ratio of 1:(1-1.5):(2-2.5), b) dissolving ketoprofen, lysine and gabapentin until a clear solution is obtained, c) The solution is then cooled.

14. The method according to claim 13, wherein step b) is dissolving ketoprofen, lysine and gabapentin by heating the suspension and / or under stirring until a clear solution is obtained.

15. The method according to claim 13, further comprising: include: d) Add anti-solvent tetrahydrofuran.

16. The method according to claim 13, wherein the ketoprofen and lysine in step a) are in the form of ketoprofen lysine salt or co-crystal.

17. The method of claim 13, wherein the ketoprofen is a free acid and / or the lysine is a neutral form.

18. The method of claim 13, wherein the gabapentin is in a neutral form.

19. The method of claim 13, wherein the gabapentin is a zwitterionic inner salt.

20. The method of claim 13, wherein in step a), the molar ratio of gabapentin to ketoprofen is 2:1 to 2.2:

1.

21. The method according to claim 20, wherein in step a), the molar ratio of gabapentin to ketoprofen is 2:1.

Citation Information

Patent Citations

  • LYSINE salt OF META-BENZOYL-HYDRATROPIC ACID, METHOD FOR PREPARING IT AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME

    BE882889A

  • Co-crystal of ketoprofen, compositions comprising the same, process of producing the same, and uses thereof

    EP3670489A1

  • Salts of phenyl-alkanoic acids

    GB1497044A

  • Synergistic combinations of non-steroidal antiinflammatory drugs with alpha-2 delta-ligands

    CN101180045A

  • Co-crystals of duloxetine and Cox-inhibitors for the treatment of pain

    CN102036946A